Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2018 | Original Article

A score combining baseline neutrophilia and primary tumor SUV_peak measured from FDG PET is associated with outcome in locally advanced cervical cancer

Authors: Antoine Schernberg, Sylvain Reuze, Fanny Orlhac, Irène Buvat, Laurent Dercle, Roger Sun, Elaine Limkin, Alexandre Escande, Christine Haie-Meder, Eric Deutsch, Cyrus Chargari, Charlotte Robert

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2018

Abstract

Purpose

We investigated whether a score combining baseline neutrophilia and a PET biomarker could predict outcome in patients with locally advanced cervical cancer (LACC).

Methods

Patients homogeneously treated with definitive chemoradiation plus image-guided adaptive brachytherapy (IGABT) between 2006 and 2013 were analyzed retrospectively. We divided patients into two groups depending on the PET device used: a training set (TS) and a validation set (VS). Primary tumors were semi-automatically delineated on PET images, and 11 radiomics features were calculated (LIFEx software). A PET radiomic index was selected using the time-dependent area under the curve (td-AUC) for 3-year local control (LC). We defined the neutrophil SUV grade (NSG = 0, 1 or 2) score as the number of risk factors among (i) neutrophilia (neutrophil count >7 G/L) and (ii) high risk defined from the PET radiomic index. The NSG prognostic value was evaluated for LC and overall survival (OS).

Results

Data from 108 patients were analyzed. Estimated 3-year LC was 72% in the TS (n = 69) and 65% in the VS (n = 39). In the TS, SUV_peak was selected as the most LC-predictive biomarker (td-AUC = 0.75), and was independent from neutrophilia (p = 0.119). Neutrophilia (HR = 2.6), high-risk SUV_peak (SUV_peak > 10, HR = 4.4) and NSG = 2 (HR = 9.2) were associated with low probability of LC in TS. In multivariate analysis, NSG = 2 was independently associated with low probability of LC (HR = 7.5, p < 0.001) and OS (HR = 5.8, p = 0.001) in the TS. Results obtained in the VS (HR = 5.2 for OS and 3.5 for LC, p < 0.02) were promising.

Conclusion

This innovative scoring approach combining baseline neutrophilia and a PET biomarker provides an independent prognostic factor to consider for further clinical investigations.

Available only for authorised users

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers D, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon Fr. Int. Agency Res. Cancer [Internet]. 2013. Available from: http://globocan.iarc.fr

Lim MC, Moon E-K, Shin A, Jung K-W, Won Y-J, Seo SS, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol. 2013;24(4):298–302. https://doi.org/10.3802/jgo.2013.24.4.298.CrossRefPubMedPubMedCentral

Narayan K, Fisher RJ, Bernshaw D, Shakher R, Hicks RJ. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. Int. J Gynecol Cancer. 2009;19:912–8.CrossRefPubMed

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed

Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016;11(1):43. https://doi.org/10.1186/s13014-016-0614-x.CrossRefPubMedPubMedCentral

Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34. https://doi.org/10.3389/fonc.2013.00034.CrossRefPubMedPubMedCentral

Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101:147–51.CrossRefPubMed

Escande A, Haie-Meder C, Maroun P, Gouy S, Mazeron R, Leroy T, et al. Neutrophilia in locally advanced cervical cancer: a novel biomarker for image-guided adaptive brachytherapy? Oncotarget. 2016;7(46):74886–94. https://doi.org/10.18632/oncotarget.12440.PubMedPubMedCentral

Mabuchi S, Matsumoto Y, Isohashi F, Yoshioka Y, Ohashi H, Morii E, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011;122:25–32.CrossRefPubMed

10.

Cho Y, Kim KH, Yoon HI, Kim GE, Kim YB. Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients. Ann Oncol. 2016;27(11):2067–74. https://doi.org/10.1093/annonc/mdw308.CrossRefPubMed

11.

Mazeron R, Castelnau-Marchand P, Dumas I, del Campo ER, Kom LK, Martinetti F, et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol. 2015;114:257–63.CrossRefPubMed

12.

Pötter R, Dimopoulos J, Georg P, Lang S, Waldhäusl C, Wachter-Gerstner N, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007;83:148–55.CrossRefPubMed

13.

Schmid MP, Franckena M, Kirchheiner K, Sturdza A, Georg P, Dörr W, et al. Distant metastasis in patients with cervical cancer after primary radiotherapy with or without chemotherapy and image guided adaptive brachytherapy. Gynecol Oncol. 2014;133:256–62.CrossRefPubMed

14.

Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer. 2000;10:305–12.CrossRefPubMed

15.

Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278(2). https://doi.org/10.1148/radiol.2015151169.

16.

Magné N, Chargari C, SanFilippo N, Messai T, Gerbaulet A, Haie-Meder C. Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies. Brachytherapy. 2010;9:274–7.CrossRefPubMed

17.

Chargari C, Magné N, Dumas I, Messai T, Vicenzi L, Gillion N, et al. Physics contributions and clinical outcome with 3D-MRI–based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol. 2009;74:133–9.CrossRef

18.

Mazeron R, Gilmore J, Dumas I, Champoudry J, Goulart J, Vanneste B, et al. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist. 2013;18:415–22.CrossRefPubMedPubMedCentral

19.

Reuze S, Orlhac F, Nioche C, Chargari C, Buvat I, Deutsch E, et al. Prediction of cervical cancer recurrence using textural features calculated from 18F–FDG PET images [Internet]. J Nucl Med. 2016;57 supplement 2:422. Available from: http://jnm.snmjournals.org/content/57/supplement_2/422.

20.

Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET∕CT Discovery-690. Med Phys. 2011;38:5394–411.CrossRefPubMed

21.

Bailly C, Bodet-Milin C, Couespel S, Necib H, Kraeber-Bodéré F, Ansquer C, et al. Revisiting the robustness of PET-based textural features in the context of multi-centric trials. PLoS One. 2016;11(7):e0159984. https://doi.org/10.1371/journal.pone.0159984.

22.

Orlhac F, Nioche C, Soussan M, Buvat I. Understanding changes in tumor textural indices in PET: a comparison between visual assessment and index values in simulated and patient data. J Nucl Med. 2016;58(3):387–92. https://doi.org/10.2967/jnumed.116.181859.CrossRefPubMed

23.

Nioche C, Orlhac F, Soussan M, Boughdad S, Alberini J, Buvat I. A software for characterizing intra-tumor heterogeneity in multimodality imaging and establishing reference charts. Eur J Nucl Med Mol Imaging. 2016;43:S156–7.

24.

Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: where do we stand? J Nucl Med. 2015;56:1642–4.CrossRefPubMed

25.

Orlhac F, Soussan M, Chouahnia K, Martinod E, Buvat I. 18F-FDG PET-derived textural indices reflect tissue-specific uptake pattern in non-small cell lung cancer. PLoS One. 2015;10:e0145063.

26.

Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55(3):414–22. https://doi.org/10.2967/jnumed.113.129858.CrossRefPubMed

27.

Schernberg A, Escande A, Rivin Del Campo E, Ducreux M, Nguyen F, Goere D, et al. Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiother Oncol. 2016;122(1):137–45. https://doi.org/10.1016/j.radonc.2016.12.009.CrossRefPubMed

28.

Aerts HJWL. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. 2016;2(12):1636–42. https://doi.org/10.1001/jamaoncol.2016.2631.CrossRefPubMed

29.

Andreassen CN, Schack LMH, Laursen LV, Alsner J. Radiogenomics – current status, challenges and future directions. Cancer Lett. 2016;382:127–36.CrossRefPubMed

30.

Ho K-C, Fang Y-HD, Chung H-W, Yen T-C, Ho T-Y, Chou H-H, et al. A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy. Am J Nucl Med Mol Imaging. 2016;6:166–75.PubMedPubMedCentral

31.

Barwick TD, Taylor A, Rockall A. Functional imaging to predict tumor response in locally advanced cervical cancer. Curr Oncol Rep. 2013;15:549–58.CrossRefPubMed

32.

Leseur J, Roman-Jimenez G, Devillers A, Ospina-Arango JD, Williaume D, Castelli J, et al. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. Radiother Oncol. 2016;120:512–8.CrossRefPubMed

33.

Pan L, Cheng J, Zhou M, Yao Z, Zhang Y. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 2012;138:239–46.CrossRefPubMed

34.

Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127:136–40.CrossRefPubMedPubMedCentral

35.

Hong JH, Min KJ, Lee JK, So KA, Jung US, Kim S, et al. Prognostic value of the sum of metabolic tumor volume of primary tumor and lymph nodes using 18F-FDG PET/CT in patients with cervical cancer. Medicine (Baltimore). 2016;95:e2992.CrossRef

36.

Mu W, Chen Z, Liang Y, Shen W, Yang F, Dai R, et al. Staging of cervical cancer based on tumor heterogeneity characterized by texture features on ¹⁸ F-FDG PET images. Phys Med Biol. 2015;60:5123–39.CrossRefPubMed

37.

Yan J, Chu-Shern JL, Loi HY, Khor LK, Sinha AK, Quek ST, et al. Impact of image reconstruction settings on texture features in 18F-FDG PET. J Nucl Med. 2015;56:1667–73.CrossRefPubMed

38.

Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.CrossRefPubMed

39.

Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16:431–46.CrossRefPubMed

40.

Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400–12. https://doi.org/10.18632/oncotarget.14541.PubMedPubMedCentral

41.

Gregory AD, McGarry HA. Tumor-associated Neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.CrossRefPubMed

Title: A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer
Authors: Antoine Schernberg
Sylvain Reuze
Fanny Orlhac
Irène Buvat
Laurent Dercle
Roger Sun
Elaine Limkin
Alexandre Escande
Christine Haie-Meder
Eric Deutsch
Cyrus Chargari
Charlotte Robert
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3824-z

At a glance: The STEP trials

Springer Medicine

A score combining baseline neutrophilia and primary tumor SUV_peak measured from FDG PET is associated with outcome in locally advanced cervical cancer

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Klaus Bohndorf, Mark Anderson, Mark Davies, Herwig Imhof, Klaus Woertler: Imaging of bones and joints. A concise, multimodality approach

18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer

Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging

The prognostic value of 18F–FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases

Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer